Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 2/20 | 0.50 |
| ▸ | CNR2 | P34972 | 9/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30634268 | 0.80 | FAAH (0.61) | PABPC1FAAHCNR2POLBTSHR | |
| SCHEMBL3315499 | 0.79 | PABPC1 (0.54) | PABPC1FAAHCNR2POLBTSHR | |
| SCHEMBL23884376 | 0.75 | ALDH1A1 (0.46) | CNR2POLBKDM4EALDH1A1HPGD | |
| SCHEMBL23900477 | 0.75 | ALDH1A1 (0.55) | POLBTSHRKDM4EALDH1A1MAPT | |
| SCHEMBL2638097 | 0.74 | NPC1 (0.56) | PABPC1FAAHCNR2TSHRKDM4E | |
| SCHEMBL23900429 | 0.74 | ALDH1A1 (0.50) | POLBTSHRKDM4EALDH1A1MAPT | |
| SCHEMBL6084070 | 0.73 | CNR2 (0.57) | PABPC1FAAHCNR2TSHRKDM4E | |
| SCHEMBL3459501 | 0.72 | CNR2 (0.57) | FAAHCNR2POLBKDM4EALDH1A1 | |
| SCHEMBL23907987 | 0.71 | FAAH (0.43) | PABPC1FAAHCNR2MAPTCNR1 | |
| SCHEMBL3456991 | 0.71 | CNR2 (0.56) | FAAHCNR2POLBATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230120566-A1 | Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | OREGON HEALTH AND SCIENCE UNIVERSITY | 2023-04-20 | — | — | US | disclosed |
| US-11566019-B2 | 2-pyrimidone analogs as potent antiviral agents against alphaviruses | SOUTHERN RESEARCH INSTITUTE (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-09 | — | — | US | disclosed |
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | SOUTHERN RES INST (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | PABPC1 55/4885FAAH 3622/4885CNR2 4380/4885 |
| US-11566019-B2 | 2-pyrimidone analogs as potent antiviral agents against alphaviruses | EIF2AK2, ZC3HAV1, MAVS | PABPC1 55/4885FAAH 3622/4885CNR2 4380/4885 |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | PABPC1 55/4885FAAH 3622/4885CNR2 4380/4885 |
| US-20230120566-A1 | Novel 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | PABPC1 69/4885FAAH 3551/4885CNR2 4247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.